PCSA
Processa Pharmaceuticals, Inc.$2.26-0.11 (-4.64%)Prev Close$2.37·MCap$6.3M·P/E—·Vol51.3K·Yield—
▲
Buys (12M)
31
$155.9K
▼
Sells (12M)
0
$0.00
◆
Net Activity
Net Buyer
$155.9K
●
Active Insiders
8
last 12 mo
Over the past 12 months, insider activity at Processa Pharmaceuticals, Inc. (PCSA) has been exclusively buying, with 31 insider purchases totaling $155.9K and 0 insider sales totaling $0.00. The most recent insider transaction was by Guy Wendy (officer: Chief Administrative Officer), who purchased $4.7K worth of shares on Jun 1, 2026. Processa Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $6.3M.
PCSA Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Guy Wendy | officer: Chief Administrative Officer | Buy | 1,829 | $2.57 | $4.7K | 9,840 |
| Jun 1, 2026 | SKIBSTED RUSSELL | officer: Chief Financial Officer | Buy | 2,292 | $2.57 | $5.9K | 10,758+27% |
| Jun 1, 2026 | Lin Patrick | officer: Chief Business - Strategy Off | Buy | 1,582 | $2.57 | $4.1K | 9,176 |
| Jun 1, 2026 | Young David | director, officer: Pres. Research & Development | Buy | 1,786 | $2.57 | $4.6K | 17,131 |
| Jun 1, 2026 | Ng George K | director, officer: Chief Executive Officer | Buy | 2,129 | $2.57 | $5.5K | 9,970+27% |
| May 19, 2026 | Ng George K | director, officer: Chief Executive Officer | Buy | 1,843 | $2.97 | $5.5K | 7,841+31% |
| May 19, 2026 | Bigora Sian | officer: Chief Development Officer | Buy | 1,971 | $2.71 | $5.3K | 7,481+36% |
| May 19, 2026 | Young David | director, officer: Pres. Research & Development | Buy | 1,545 | $2.97 | $4.6K | 15,345 |
| May 19, 2026 | Guy Wendy | officer: Chief Administrative Officer | Buy | 1,583 | $2.97 | $4.7K | 8,011 |
| May 19, 2026 | Lin Patrick | officer: Chief Business - Strategy Off | Buy | 1,369 | $2.97 | $4.1K | 7,594 |
| May 19, 2026 | SKIBSTED RUSSELL | officer: Chief Financial Officer | Buy | 1,984 | $2.97 | $5.9K | 8,466+31% |
| May 1, 2026 | Young David | director, officer: Pres. Research & Development | Buy | 1,706 | $2.69 | $4.6K | 13,813 |
| May 1, 2026 | Guy Wendy | officer: Chief Administrative Officer | Buy | 1,748 | $2.69 | $4.7K | 6,441+37% |
| May 1, 2026 | Bigora Sian | officer: Chief Development Officer | Buy | 1,986 | $2.69 | $5.3K | 7,496+36% |
| May 1, 2026 | Lin Patrick | officer: Chief Business - Strategy Off | Buy | 1,511 | $2.69 | $4.1K | 6,236+32% |
| May 1, 2026 | Ng George K | director, officer: Chief Executive Officer | Buy | 2,034 | $2.69 | $5.5K | 6,013+51% |
| May 1, 2026 | SKIBSTED RUSSELL | officer: Chief Financial Officer | Buy | 2,190 | $2.69 | $5.9K | 6,498+51% |
| Apr 17, 2026 | SKIBSTED RUSSELL | officer: Chief Financial Officer | Buy | 1,984 | $2.97 | $5.9K | 4,308+85% |
| Apr 17, 2026 | Bigora Sian | officer: Chief Development Officer | Buy | 1,799 | $2.97 | $5.3K | 5,510+48% |
| Apr 17, 2026 | Guy Wendy | officer: Chief Administrative Officer | Buy | 1,583 | $2.97 | $4.7K | 4,693+51% |
| Apr 17, 2026 | Ng George K | director, officer: Chief Executive Officer | Buy | 1,843 | $2.97 | $5.5K | 5,492+51% |
| Apr 17, 2026 | Young David | director, officer: Pres. Research & Development | Buy | 1,545 | $2.97 | $4.6K | 12,107 |
| Apr 17, 2026 | Lin Patrick | officer: Chief Business - Strategy Off | Buy | 1,369 | $2.97 | $4.1K | 4,725+41% |
| Apr 1, 2026 | Young David | director, officer: Pres. Research & Development | Buy | 1,810 | $2.54 | $4.6K | 10,562 |
| Apr 1, 2026 | Baluch Khoso | director | Buy | 2,269 | $2.53 | $5.8K | 2,325New Position |
| Apr 1, 2026 | Bigora Sian | officer: Chief Development Officer | Buy | 2,107 | $2.53 | $5.3K | 3,711+131% |
| Apr 1, 2026 | Guy Wendy | officer: Chief Administrative Officer | Buy | 1,854 | $2.54 | $4.7K | 3,110+148% |
| Apr 1, 2026 | Lin Patrick | officer: Chief Business - Strategy Off | Buy | 1,603 | $2.54 | $4.1K | 3,356+91% |
| Apr 1, 2026 | SKIBSTED RUSSELL | officer: Chief Financial Officer | Buy | 2,324 | $2.53 | $5.9K | 2,324 |
| Apr 1, 2026 | Ng George K | director, officer: Chief Executive Officer | Buy | 2,136 | $2.53 | $5.4K | 3,649+141% |
| Apr 1, 2026 | Pannu Geraldine | director | Buy | 2,072 | $2.54 | $5.3K | 2,188New Position |
| Apr 1, 2025 | Young David | Pres. Research & Development | Sell | 5,345 | $0.41 | $2.2K | 0 |
| Jan 31, 2025 | Yorke Justin W | Buy | 12,400 | $0.80 | $9.9K0.5% OS | 12,400 | |
| Jan 29, 2025 | Lin Patrick | Chief Business - Strategy Off | Buy | 43,500 | $0.80 | $34.7K1.9% OS | 43,500 |
| Jan 29, 2025 | Ng George K | Chief Executive Officer | Buy | 87,200 | $0.80 | $69.5K3.8% OS | 87,200 |
| Jan 29, 2025 | Young David | Pres. Research & Development | Buy | 124,500 | $0.80 | $99.3K5.5% OS | 205,405+154% |
| Feb 8, 2024 | Young David | Pres. Research & Development | Buy | 21,000 | $2.45 | $51.5K0.9% OS | 79,387+36% |
| Feb 7, 2024 | Young David | Pres. Research & Development | Buy | 20,000 | $2.53 | $50.5K0.9% OS | 58,387+52% |
| Feb 1, 2024 | Lin Patrick | Chief Business - Strategy Off | Buy | 4,000 | $2.38 | $9.5K | 27,478 |
| Jan 31, 2024 | Ng George K | Chief Executive Officer | Buy | 10,000 | $2.70 | $27.0K | 20,000+100% |
| Jan 31, 2024 | Yorke Justin W | Buy | 8,000 | $2.69 | $21.5K | 31,232+34% | |
| Jun 12, 2023 | Young David | President & CEO | Buy | 40,000 | $0.80 | $32.0K1.8% OS | 470,424 |
| Apr 14, 2023 | Young David | President & CEO | Buy | 20,000 | $0.55 | $11.0K0.9% OS | 430,424 |
| Apr 13, 2023 | Young David | President & CEO | Buy | 60,000 | $0.48 | $29.0K2.6% OS | 410,424 |
| May 19, 2022 | Lin Patrick | Chief Business - Strategy Off | Buy | 2,000 | $1.59 | $3.2K | 433,390 |
| Apr 8, 2022 | Lin Patrick | Chief Business - Strategy Off | Buy | 2,000 | $3.29 | $6.6K | 431,390 |
| Jan 31, 2022 | Yorke Justin W | Director | Sell | 1,854 | $3.30 | $6.1K | 532,563 |
| Jan 4, 2022 | Lin Patrick | Chief Business - Strategy Off | Buy | 3,000 | $4.00 | $12.0K | 429,390 |
| Dec 7, 2021 | Lin Patrick | Chief Business - Strategy Off | Buy | 3,500 | $4.80 | $16.8K | 426,390 |
| Dec 7, 2021 | Yorke Justin W | Director | Sell | 9,700 | $4.78 | $46.4K | 538,617 |
Showing 1–50 of 57
1 / 2
PCSA Insider Buying Activity
The following table shows recent insider purchases of Processa Pharmaceuticals, Inc. (PCSA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Guy Wendy | officer: Chief Administrative Officer | Buy | 1,829 | $2.57 | $4.7K | 9,840 |
| Jun 1, 2026 | SKIBSTED RUSSELL | officer: Chief Financial Officer | Buy | 2,292 | $2.57 | $5.9K | 10,758+27% |
| Jun 1, 2026 | Lin Patrick | officer: Chief Business - Strategy Off | Buy | 1,582 | $2.57 | $4.1K | 9,176 |
| Jun 1, 2026 | Young David | director, officer: Pres. Research & Development | Buy | 1,786 | $2.57 | $4.6K | 17,131 |
| Jun 1, 2026 | Ng George K | director, officer: Chief Executive Officer | Buy | 2,129 | $2.57 | $5.5K | 9,970+27% |
| May 19, 2026 | Ng George K | director, officer: Chief Executive Officer | Buy | 1,843 | $2.97 | $5.5K | 7,841+31% |
| May 19, 2026 | Bigora Sian | officer: Chief Development Officer | Buy | 1,971 | $2.71 | $5.3K | 7,481+36% |
| May 19, 2026 | Young David | director, officer: Pres. Research & Development | Buy | 1,545 | $2.97 | $4.6K | 15,345 |
| May 19, 2026 | Guy Wendy | officer: Chief Administrative Officer | Buy | 1,583 | $2.97 | $4.7K | 8,011 |
| May 19, 2026 | Lin Patrick | officer: Chief Business - Strategy Off | Buy | 1,369 | $2.97 | $4.1K | 7,594 |
| May 19, 2026 | SKIBSTED RUSSELL | officer: Chief Financial Officer | Buy | 1,984 | $2.97 | $5.9K | 8,466+31% |
| May 1, 2026 | Young David | director, officer: Pres. Research & Development | Buy | 1,706 | $2.69 | $4.6K | 13,813 |
| May 1, 2026 | Guy Wendy | officer: Chief Administrative Officer | Buy | 1,748 | $2.69 | $4.7K | 6,441+37% |
| May 1, 2026 | Bigora Sian | officer: Chief Development Officer | Buy | 1,986 | $2.69 | $5.3K | 7,496+36% |
| May 1, 2026 | Lin Patrick | officer: Chief Business - Strategy Off | Buy | 1,511 | $2.69 | $4.1K | 6,236+32% |
| May 1, 2026 | Ng George K | director, officer: Chief Executive Officer | Buy | 2,034 | $2.69 | $5.5K | 6,013+51% |
| May 1, 2026 | SKIBSTED RUSSELL | officer: Chief Financial Officer | Buy | 2,190 | $2.69 | $5.9K | 6,498+51% |
| Apr 17, 2026 | SKIBSTED RUSSELL | officer: Chief Financial Officer | Buy | 1,984 | $2.97 | $5.9K | 4,308+85% |
| Apr 17, 2026 | Bigora Sian | officer: Chief Development Officer | Buy | 1,799 | $2.97 | $5.3K | 5,510+48% |
| Apr 17, 2026 | Guy Wendy | officer: Chief Administrative Officer | Buy | 1,583 | $2.97 | $4.7K | 4,693+51% |
| Apr 17, 2026 | Ng George K | director, officer: Chief Executive Officer | Buy | 1,843 | $2.97 | $5.5K | 5,492+51% |
| Apr 17, 2026 | Young David | director, officer: Pres. Research & Development | Buy | 1,545 | $2.97 | $4.6K | 12,107 |
| Apr 17, 2026 | Lin Patrick | officer: Chief Business - Strategy Off | Buy | 1,369 | $2.97 | $4.1K | 4,725+41% |
| Apr 1, 2026 | Young David | director, officer: Pres. Research & Development | Buy | 1,810 | $2.54 | $4.6K | 10,562 |
| Apr 1, 2026 | Baluch Khoso | director | Buy | 2,269 | $2.53 | $5.8K | 2,325New Position |
| Apr 1, 2026 | Bigora Sian | officer: Chief Development Officer | Buy | 2,107 | $2.53 | $5.3K | 3,711+131% |
| Apr 1, 2026 | Guy Wendy | officer: Chief Administrative Officer | Buy | 1,854 | $2.54 | $4.7K | 3,110+148% |
| Apr 1, 2026 | Lin Patrick | officer: Chief Business - Strategy Off | Buy | 1,603 | $2.54 | $4.1K | 3,356+91% |
| Apr 1, 2026 | SKIBSTED RUSSELL | officer: Chief Financial Officer | Buy | 2,324 | $2.53 | $5.9K | 2,324 |
| Apr 1, 2026 | Ng George K | director, officer: Chief Executive Officer | Buy | 2,136 | $2.53 | $5.4K | 3,649+141% |
| Apr 1, 2026 | Pannu Geraldine | director | Buy | 2,072 | $2.54 | $5.3K | 2,188New Position |
| Jan 31, 2025 | Yorke Justin W | Buy | 12,400 | $0.80 | $9.9K0.5% OS | 12,400 | |
| Jan 29, 2025 | Lin Patrick | Chief Business - Strategy Off | Buy | 43,500 | $0.80 | $34.7K1.9% OS | 43,500 |
| Jan 29, 2025 | Ng George K | Chief Executive Officer | Buy | 87,200 | $0.80 | $69.5K3.8% OS | 87,200 |
| Jan 29, 2025 | Young David | Pres. Research & Development | Buy | 124,500 | $0.80 | $99.3K5.5% OS | 205,405+154% |
| Feb 8, 2024 | Young David | Pres. Research & Development | Buy | 21,000 | $2.45 | $51.5K0.9% OS | 79,387+36% |
| Feb 7, 2024 | Young David | Pres. Research & Development | Buy | 20,000 | $2.53 | $50.5K0.9% OS | 58,387+52% |
| Feb 1, 2024 | Lin Patrick | Chief Business - Strategy Off | Buy | 4,000 | $2.38 | $9.5K | 27,478 |
| Jan 31, 2024 | Ng George K | Chief Executive Officer | Buy | 10,000 | $2.70 | $27.0K | 20,000+100% |
| Jan 31, 2024 | Yorke Justin W | Buy | 8,000 | $2.69 | $21.5K | 31,232+34% | |
| Jun 12, 2023 | Young David | President & CEO | Buy | 40,000 | $0.80 | $32.0K1.8% OS | 470,424 |
| Apr 14, 2023 | Young David | President & CEO | Buy | 20,000 | $0.55 | $11.0K0.9% OS | 430,424 |
| Apr 13, 2023 | Young David | President & CEO | Buy | 60,000 | $0.48 | $29.0K2.6% OS | 410,424 |
| May 19, 2022 | Lin Patrick | Chief Business - Strategy Off | Buy | 2,000 | $1.59 | $3.2K | 433,390 |
| Apr 8, 2022 | Lin Patrick | Chief Business - Strategy Off | Buy | 2,000 | $3.29 | $6.6K | 431,390 |
| Jan 4, 2022 | Lin Patrick | Chief Business - Strategy Off | Buy | 3,000 | $4.00 | $12.0K | 429,390 |
| Dec 7, 2021 | Lin Patrick | Chief Business - Strategy Off | Buy | 3,500 | $4.80 | $16.8K | 426,390 |
PCSA Insider Selling Activity
The following table shows recent insider sales of Processa Pharmaceuticals, Inc. (PCSA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 1, 2025 | Young David | Pres. Research & Development | Sell | 5,345 | $0.41 | $2.2K | 0 |
| Jan 31, 2022 | Yorke Justin W | Director | Sell | 1,854 | $3.30 | $6.1K | 532,563 |
| Dec 7, 2021 | Yorke Justin W | Director | Sell | 9,700 | $4.78 | $46.4K | 538,617 |
PCSA Insiders
Similar Stocks to PCSA
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B